{"nctId":"NCT01818492","briefTitle":"Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis","startDateStruct":{"date":"2013-07","type":"ACTUAL"},"conditions":["Primary Haemophagocytic Lymphohistiocytosis"],"count":45,"armGroups":[{"label":"NI-0501","type":"EXPERIMENTAL","interventionNames":["Biological: NI-0501"]}],"interventions":[{"name":"NI-0501","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Gender: male and female\n* Age: up to and including 18 years at diagnosis of Haemophagocytic Lymphohistiocytosis\n* Primary HLH patients\n* Patient (if ≥ 18 years old), or patient's legal representative(s) must have signed informed consent\n\nExclusion Criteria:\n\n* Diagnosis of secondary Haemophagocytic Lymphohistiocytosis consequent to a proven rheumatic or neoplastic disease.\n* Body weight \\< 3 kg.\n* Patients treated with biologics within a specific timeframe\n* Active Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter and Leishmania infections.\n* Presence of malignancy.\n* Concomitant disease or malformation severely affecting the cardiovascular, pulmonary, liver or renal function","healthyVolunteers":false,"sex":"ALL","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Response Rate (ORR) Second Line","description":"Achievement of either Complete (CR) or Partial Response (PR), or HLH Improvement (HI) at End of Treatment of Study NI 0501-04 (EOT 04), based on pre-specified algorithm.\n\nCR: no fever, normal spleen size, no cytopenia (ANC ≥ 1.0x109/L and platelet count ≥ 100x109/L), no hyperferritinemia (serum ferritin \\<2000 μg), no coagulopathy (normal D-dimer and/or fibrinogen \\>150 mg/dL), no neurological and CSF abnormalities attributed to HLH, no sustained worsening of sCD25.\n\nPR: at least 3 HLH clinical and laboratory criteria (including CNS abnormalities) met the CR criteria, no progression of other aspects of HLH disease pathology.\n\nHI: improvement (\\>50% change from baseline) of at least 3 HLH clinical and laboratory criteria (including CNS involvement).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Response Rate (ORR) All Treated","description":"Achievement of either Complete (CR) or Partial Response (PR), or HLH Improvement (HI) at End of Treatment of Study NI 0501-04 (EOT 04), based on pre-specified algorithm.\n\nCR: no fever, normal spleen size, no cytopenia (ANC ≥ 1.0x109/L and platelet count ≥ 100x109/L), no hyperferritinemia (serum ferritin \\<2000 μg), no coagulopathy (normal D-dimer and/or fibrinogen \\>150 mg/dL), no neurological and CSF abnormalities attributed to HLH, no sustained worsening of sCD25.\n\nPR: at least 3 HLH clinical and laboratory criteria (including CNS abnormalities) met the CR criteria, no progression of other aspects of HLH disease pathology.\n\nHI: improvement (\\>50% change from baseline) of at least 3 HLH clinical and laboratory criteria (including CNS involvement).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Response Rate (ORR) Follow-on Analysis Set:","description":"Achievement of either Complete (CR) or Partial Response (PR), or HLH Improvement (HI) at End of Treatment of Study NI 0501-04 (EOT 04), based on pre-specified algorithm.\n\nCR: no fever, normal spleen size, no cytopenia (ANC ≥ 1.0x109/L and platelet count ≥ 100x109/L), no hyperferritinemia (serum ferritin \\<2000 μg), no coagulopathy (normal D-dimer and/or fibrinogen \\>150 mg/dL), no neurological and CSF abnormalities attributed to HLH, no sustained worsening of sCD25.\n\nPR: at least 3 HLH clinical and laboratory criteria (including CNS abnormalities) met the CR criteria, no progression of other aspects of HLH disease pathology.\n\nHI: improvement (\\>50% change from baseline) of at least 3 HLH clinical and laboratory criteria (including CNS involvement).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Response Rate (ORR) at End of Treatment in Study NI-0501-04 (EOT 04) Follow-on Analysis Set: All Treated","description":"Achievement of either Complete (CR) or Partial Response (PR), or HLH Improvement (HI) at End of Treatment of Study NI 0501-04 (EOT 04), based on pre-specified algorithm.\n\nCR: no fever, normal spleen size, no cytopenia (ANC ≥ 1.0x109/L and platelet count ≥ 100x109/L), no hyperferritinemia (serum ferritin \\<2000 μg), no coagulopathy (normal D-dimer and/or fibrinogen \\>150 mg/dL), no neurological and CSF abnormalities attributed to HLH, no sustained worsening of sCD25.\n\nPR: at least 3 HLH clinical and laboratory criteria (including CNS abnormalities) met the CR criteria, no progression of other aspects of HLH disease pathology.\n\nHI: improvement (\\>50% change from baseline) of at least 3 HLH clinical and laboratory criteria (including CNS involvement).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Response","description":"Time from the date of the first dose of emapalumab to first achievement of response (at least HLH improvement)","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Durability of First Response","description":"Maintenance of response achieved any time during the study","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Number of patients being alive at end of treatment or at week 8, pending on which comes first.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Reduce Glucocorticoids","description":"Number of patients able to reduce glucocorticoids by 50% or more and between ≥30%-\\<50%, of baseline dose at EOT 04.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Duration of Response","description":"Percent of treatment time in response from the first achievement of an Overall Response until HSCT conditioning, or End of Treatment 04/05 (if the patient did not have HSCT performed) Where applicable, data were collected in both NI-0501-04 and long-term follow-up study NI-0501-05.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Survival Pre-HSCT","description":"Time from the date of first dose to the date of death, expressed in Kaplan-Meier survival probability estimates. Patients who receive HSCT will be censored at that date; patients who did not receive HSCT will be censored at last date of contact.\n\nWhere applicable, data were collected in both NI-0501-04 and long-term follow-up study NI-0501-05.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":null}]}]}]},{"type":"SECONDARY","title":"Survival Post-HSCT","description":"Time from the date of first dose to the date of death, expressed in Kaplan-Meier survival probability estimates. Patients without an event will be censored at last assessment date in either the NI-0501-04 or NI-0501-05 study. Patients who do not proceed to HSCT will be excluded from this analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":45},"commonTop":["Pyrexia","Hypertension","Condition aggravated","Diarrhoea","Rash"]}}}